Whole exome-seq and RNA-seq data reveal unique neoantigen profiles in Kenyan breast cancer patients
The unique neoantigen profiles in our patient group highlight the potential of immunotherapy in personalized breast cancer treatment as well as potential biomarkers for prognosis. The unique mutations producing these neoantigens, compared to other populations, provide an opportunity for validation in a much larger sample cohort.
Authors
- Stefan Ambs (ORCID: https://orcid.org/0000-0001-7651-9309)
- Mary Murithi (ORCID: https://orcid.org/0000-0002-4586-684X)
- Elias Melly
- Kennedy Mwangi (ORCID: https://orcid.org/0000-0003-2561-1521)
- Shahin Sayed (ORCID: https://orcid.org/0000-0002-3472-511X)
- John Gitau
- Francis Makokha (ORCID: https://orcid.org/0000-0003-3324-4426)
- Godfrey Wagutu
- Alexandra R. Harris
Institutions
- Mount Kenya University (KE)
- Aga Khan University Hospital Nairobi (KE)
- Kabarak University (KE)
- Aga Khan University Nairobi (KE)
- African Institute for Mathematical Sciences (RW)
- National Cancer Institute (US)
- International Livestock Research Institute (KE)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-12-11
- DOI
- https://doi.org/10.3389/fonc.2024.1444327
- Citations
- 3
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.72
Funders
- Innovative Research Group Project of the National Natural Science Foundation of China
- Fonds National de la Recherche Luxembourg
- National Cancer Institute